On April 23, 2026, the U.S. DOJ moved state-licensed medical cannabis to Schedule III, the first federal acknowledgment of accepted medical value in 55 years. Dr. Caplan breaks down what actually changed for patients, physicians, and the research pipeline.
Trump administration moves medical marijuana to Schedule III – WLOX
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyResearchFederal RegulationMedical CannabisSchedule Iii Why This Matters Schedule III reclassification removes the most significant...
Terrapin calls for state action following DOJ’s medical marijuana rescheduling | News
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Federal PolicyMedical CannabisRegulationResearch AccessSchedule Iii Why This Matters Federal rescheduling from Schedule I to...
New Mexico cannabis businesses see tax break potential after federal rescheduling – KOB 4
✦ New CED Clinical Relevance #82High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic PolicyAccessEconomicsRegulationSchedule Iii Why This Matters Federal rescheduling from Schedule I to Schedule III...
Medical marijuana moves to Schedule III, boosting research and tax relief, but no change to …
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyResearchSchedule IiiAccessRegulation Why This Matters Schedule III reclassification removes significant regulatory barriers that have...
UNLV scientists say the federal move reclassifying cannabis to Schedule III won’t legalize it …
✦ New CED Clinical Relevance #82High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic PolicyRegulationSchedule IiiMedical CannabisClinical Practice Why This Matters The proposed Schedule III reclassification creates...
What the DOJ Cannabis Order Means for Patients and Clinicians
The medical cannabis Schedule III order is a major federal policy change, but it is not the same as new clinical proof. This Evidence Watch explains what the DOJ action may mean for research access, patient care, and regulated medical cannabis programs. It also clarifies what Schedule III does not show about cannabis safety, dosing, or effectiveness for specific conditions.
Changes could be coming to Oklahoma after medical marijuana reclassified – KOCO
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyFederal RegulationMedical CannabisSchedule IiiResearch Why This MattersFederal reclassification of cannabis from Schedule I to...
Arkansas medical marijuana businesses brace for changes amid federal reclassification
✦ New CED Clinical Relevance #88High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic PolicyFederal RegulationMedical CannabisSchedule IiiState Programs Why This MattersFederal reclassification from Schedule I to...
U of M Cannabis Research Center: medical marijuana scheduling change could expand … – KEYC
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic ResearchFederal PolicySchedule IiiClinical TrialsRegulation Why This MattersFederal rescheduling of cannabis would remove significant regulatory...